Cardiol Therapeutics receives over USD 7 million from warrant exercises
CRDL•Remaining warrants and acceleration terms
Warrants are subject to an acceleration right triggered as of Sept. 15, 2026.
425,000 warrants remained unexercised, implying additional potential gross proceeds of USD 573,750.
Accelerated warrants will expire at 4:00 p.m. ET on Oct. 16, 2026; unexercised warrants will be cancelled.
Warrant exercises bring in over USD 7 million
Cardiol Therapeutics received over USD 7 million from exercises of outstanding common share purchase warrants.
Cash runway now extends into H1 2028 ahead of the Phase III MAVERIC topline data readout in recurrent pericarditis.
